Search research articles
Contact Us
Filters
Showing results (41-50 of 83) with videos related to
Page
of 9
Sort By:
The Lancet. Oncology
|
May 29, 2021
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al.
European Urology Oncology
|
February 22, 2021
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial
Bernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, et al.
Frontiers in Oncology
|
November 23, 2020
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
Natalia Jiménez, Òscar Reig, Ruth Montalbo, et al.
Cancers
|
October 14, 2022
Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
Natalia Jiménez, Òscar Reig, Mercedes Marín-Aguilera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 20, 2026
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer
Francesca Jackson-Spence, James Larkin, Poulam Patel, et al.
British Journal of Cancer
|
December 15, 2023
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
Albert Font, Begona Mellado, Miguel A Climent, et al.
European Urology
|
April 5, 2024
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial
Sumanta K Pal, Petros Grivas, Shilpa Gupta, et al.
Science Translational Medicine
|
May 10, 2023
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Ignacio Melero, Tamara Tanos, Mariana Bustamante, et al.
Cancer Research
|
September 2, 2020
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer
Joaquim Bellmunt, Jaegil Kim, Brendan Reardon, et al.
Clinical and Translational Science
|
February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
Debbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 83) with videos related to
Sort By:
Page
of 9
The Lancet. Oncology
|
May 29, 2021
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al.
European Urology Oncology
|
February 22, 2021
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial
Bernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, et al.
Frontiers in Oncology
|
November 23, 2020
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
Natalia Jiménez, Òscar Reig, Ruth Montalbo, et al.
Cancers
|
October 14, 2022
Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
Natalia Jiménez, Òscar Reig, Mercedes Marín-Aguilera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 20, 2026
CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer
Francesca Jackson-Spence, James Larkin, Poulam Patel, et al.
British Journal of Cancer
|
December 15, 2023
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
Albert Font, Begona Mellado, Miguel A Climent, et al.
European Urology
|
April 5, 2024
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial
Sumanta K Pal, Petros Grivas, Shilpa Gupta, et al.
Science Translational Medicine
|
May 10, 2023
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Ignacio Melero, Tamara Tanos, Mariana Bustamante, et al.
Cancer Research
|
September 2, 2020
Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer
Joaquim Bellmunt, Jaegil Kim, Brendan Reardon, et al.
Clinical and Translational Science
|
February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
Debbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
Page
of 9